Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of August 2023. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of July 31, 2023, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification regarding share capital structure rather than a financial performance report.
| Metric | Value |
|---|---|
| Issued Share Capital (as of July 31, 2023) | 4,312,079,013 Ordinary Shares (31 1/2 pence each) |
| Treasury Shares | 217,068,169 |
| Total Voting Rights | 4,095,010,844 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document focuses on the static share count as of the reporting date to assist shareholders in calculating notification thresholds.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose is to establish the denominator for shareholder interest calculations under FCA rules.
Important Facts for Investors
- Voting Rights Denominator: Shareholders should use 4,095,010,844 as the total number of voting rights to determine if they must notify the Company of their interest or changes thereto.
- Share Structure: As of July 31, 2023, the Company held 217,068,169 shares in Treasury, reducing the total voting rights from the total issued share count.
- Contact for Notifications: Shareholder notifications should be sent to company.secretary@gsk.com.